ABC | Volume 114, Nº4, April 2020

Original Article Albuquerque et al. Ser49Gly Polymorphism in heart failure Arq Bras Cardiol. 2020; 114(4):613-615 Table 1 — Baseline characteristics of the population according to the genetic polymorphisms of Ser49Gly β1-adrenergic receptor Clinical Variable* Total Ser49Gly β1 Genetic Polymorphism Ser-Ser (n = 122) Ser-Gly (n = 51) Gly-Gly (n = 5) p Men n % 113 (63.5%) 79 (64.8%) 31 (60.8%) 3 (60.0%) 0.873 Follow-up (years) 6.7 ± 4.4 Duration of HF (months) 8.9 ± 6.1 Age (years) 64.4 ± 12.8 Skin Color White 98 (55.1%) 76 (62.3%) 22 (43.1%) 0 (0.0%) 0.003 Black 28 (15.7%) 20 (16.4%) 6 (11.8%) 2 (40.0%) Other 52 (29.2%) 26 (24.3%) 23 (45.1%) 3 (60.0%) Etiology CAD 56 (31.5%) 43 (35.2%) 12 (23.5%) 1 (20.0%) 0.093 Idiopathic 42 (23.6%) 27 (22.1%) 13 (25.5%) 2 (40.0%) Hypert 28 (15.7%) 13 (10.7%) 13 (25.5%) 2 (40.0%) Alcohol 19 (10.7%) 12 (9.8%) 7 (13.7%) 0 (0.0%) Other 33 (18.5%) 27 (22.1%) 6 (11.8%) 0 (0.0%) Baseline NYHA † I 47 (26.6%) 36 (29.8%) 9 (17.6%) 2 (40.0%) 0.334 II 70 (39.5%) 50 (41.3%) 19 (37.3%) 1 (20.0%) III 47 (26.6%) 28 (23.1%) 17 (33.3%) 2 (40.0%) IV 13 (7.3%) 7 (5.8%) 6 (11.8%) 0 (0.0%) Mean 2.15 ± 0.9 2.05 ± 0.9 2.39 ± 0.9 2.0 ± 1.0 0.068 Baseline LVEF (%) 34.8 ± 10.7 35.3 ± 11.2 33.5 ± 8.1 37.4 ± 2.1 0.54 Hypert n % 134 (75.7%) 88 (72.7%) 42 (82.4%) 4 (80.0%) 0.395 DM n % 60 (33.7%) 39 (32.0%) 19 (37.3%) 2 (40.0%) 0.763 AF n % 41 (24.0%) 29 (24.8%) 12 (24.5%) 0 (0.0%) 0.492 Lab Hemoglobin (mg/dL) 13.2 ± 1.9 13.2 ± 2.0 13.1 ± 1.7 13.8 ± 2.2 0.734 Sodium (mEq/L) 139.8 ± 3.4 139.9 ± 3.4 139.8 ± 3.3 139.0 ± 4.6 0.843 Potassium (mEq/L) 4.47 ± 0.7 4.46 ± 0.7 4.52 ± 0.6 4.38 ± 0.5 0.836 Creatinine (mg/dL) 1.41 ± 1.0 1.50 ± 1.1 1.23 ± 0.5 1.06 ± 0.2 0.199 Treatment BB n % 173 (97.2%) 118 (96.7%) 50 (98.0%) 5 (100.0%) 0.828 ACEI n % 79 (44.4%) 52 (42.6%) 23 (45.1%) 4 (80.0%) 0.255 ARB n % 54 (30.3%) 37 (30.3%) 16 (31.4%) 1 (20.0%) 0.87 Spiro n % 83 (46.6%) 52 (42.6%) 27 (52.9%) 4 (80.0%) 0.147 Digox n % 47 (26.4%) 30 (24.6%) 15 (29.4%) 2 (40.0%) 0.631 Low adherence n % 81 (46.0%) 52 (43.0%) 27 (54.0%) 2 (40.0%) 0.405 Furosemide (dose-mg) 90.8 ± 64.3 97.3 ± 66.8 81.0 ± 59.8 55.0 ± 30.0 0.22 *Numerical variables are expressed as mean ± standard deviation; categorical variables expressed as [n e (%)]. Follow-up: follow-up time (in years); duration of HF: duration of disease course since the date of diagnosis (in years); CAD: Coronary Artery Disease; Hypert: Systemic Arterial Hypertension; NYHA: New York Heart Association Functional Class; LVEF: Left Ventricular Ejection Fraction; DM: Diabetes Mellitus; AF: Atrial Fibrillation; LBBB: Left Bundle Branch Block; Hb: Hemoglobin (in mg/dL); BB: Betablocker;ACEI:Angiotensin-converting enzyme inhibitor;ARB:Angiotensin receptor blocker; Spiro: Spironolactone; Digox: Digoxin. † Baseline NYHA class data were not available for 1 patient from the Ser-Ser group. 619